Iribrine Plus Tucidinostat in the Treatment of HR+/HER2 Advanced Breast Cancer After CDK4/6 Inhibitor Failure

To explore the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) and Phase II recommended dose (RP2D) of the regimen of Eribulin plus Tucidinostat , and to initially explore the safety and efficacy of Eribulin plus Tucidinostat amine in patients with HR+/ HER2-advanced metastatic breast cancer